Premium
Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia
Author(s) -
Algrin Caroline,
Golmard JeanLouis,
Michallet Mauricette,
Reman Oumedaly,
Huynh Anne,
Perrot Aurore,
Sirvent Anne,
Plesa Adriana,
Salaun Véronique,
Béné MarieChristine,
Bories Dominique,
Tournilhac Olivier,
MerleBéral Hélène,
Leblond Véronique,
Le GarffTavernier Magali,
Dhedin Nathalie
Publication year - 2017
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12836
Subject(s) - medicine , minimal residual disease , flow cytometry , chronic lymphocytic leukemia , oncology , refractory (planetary science) , multivariate analysis , transplantation , leukemia , gastroenterology , immunology , physics , astrobiology
Objectives This study investigates whether achieving complete remission ( CR ) with undetectable minimal residual disease ( MRD ) after allogeneic stem cell transplantation (allo‐ SCT ) for chronic lymphocytic leukemia ( CLL ) affects outcome. Methods We retrospectively studied 46 patients transplanted for CLL and evaluated for post‐transplant MRD by flow cytometry. Results At transplant time, 43% of the patients were in CR , including one with undetectable MRD , 46% were in partial response, and 11% had refractory disease. After transplant, 61% of the patients achieved CR with undetectable MRD status. By multivariate analysis, reaching CR with undetectable MRD 12 months after transplant was the only factor associated with better progression‐free survival ( P = 0.02) and attaining undetectable MRD , independently of the time of negativity, was the only factor that correlated with better overall survival ( P = 0.04). Conclusion Thus, achieving undetectable MRD status after allo‐ SCT for CLL is a major goal to improve post‐transplant outcome.